Protein nanoparticles as drug carriers in clinical medicine

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

Gradishar, W. J., Tjulandin, S., Davidson, N. G. P., Shaw, H., Desai, N. P., Bhar, P., Hawkins, M., & O’Shaughnessy, J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.937 · Cited by 2,159 · see citing works

Taxol stabilizes microtubules in mouse fibroblast cells.

Schiff, P. B., & Horwitz, S. B. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1561 · Cited by 1,971 · see citing works

Cremophor EL

Gelderblom, H. A. J., Verweij, J., Nooter, K., & Sparreboom, A. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00171-x · Cited by 1,659 · see citing works

Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel.

Desai, N. P., Trieu, V. N., Yao, Z., Louie, L. G., Ci, S., Yang, A. J., Tao, C., De, T., Beals, B., Dykes, D. J., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1634 · Cited by 1,183 · see citing works

Hypersensitivity reactions from taxol.

Weiss, R. B., Donehower, R. C., Wiernik, P. H., Ohnuma, T., Gralla, R. J., Trump, D. L., Baker, J. R., Echo, D. A. V., Hoff, D. D. V., & Leyland-Jones, B. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.7.1263 · Cited by 1,174 · see citing works

Paclitaxel and its formulations

Singla, A. K., Garg, A. B., & Aggarwal, D. (2002) · International Journal of Pharmaceutics · doi:10.1016/s0378-5173(01)00986-3 · Cited by 1,100 · see citing works

Taxol: A Novel Investigational Antimicrotubule Agent

Rowinsky, E. K., Cazenave, L. A., & Donehower, R. C. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.15.1247 · Cited by 1,096 · see citing works

THE IMPACT OF NATIONAL CANCER ACT

Holmes, F. A., Walters, R. S., Theriault, R. L., Buzdar, A. U., Frye, D. K., Hortobágyi, G. N., Forman, A. D., Newton, L. K., & Raber, M. N. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797 · Cited by 796 · see citing works

Phase II Trial of Taxol, an Active Drug in the Treatment of Metastatic Breast Cancer

Holmes, F. A., Walters, R. S., Theriault, R. L., Buzdar, A. U., Frye, D., Hortobágyi, G. N., Forman, A. D., Newton, L. K., & Raber, M. N. (1991) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/83.24.1797-a · Cited by 744 · see citing works

Abraxane®, a novel Cremophor®-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer

Green, M. R., Manikhas, G. M., Орлов, С. В., Afanasyev, B. V., Makhson, A. M., Bhar, P., & Hawkins, M. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl104 · Cited by 671 · see citing works

Prospective Randomized Trial of Docetaxel Versus Doxorubicin in Patients With Metastatic Breast Cancer

Chan, S. Y. T., Friedrichs, K., Noel, D., Pintér, T., Belle, S. V., Vorobiof, D., Duarte, R., Gil, M. G., Bodrogi, I., Murray, E., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.8.2341 · Cited by 638 · see citing works

Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel.

Ibrahim, N. K., Desai, N. P., Legha, S. S., Soon‐Shiong, P., Theriault, R. L., Rivera, E., Esmaeli, B., Ring, S. E., Bedikian, A. Y., Hortobágyi, G. N., et al. (2002) · PubMed · Cited by 627 · see citing works

Pharmacological Effects of Formulation Vehicles

ten Tije, A. J., Verweij, J., Loos, W. J., & Sparreboom, A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00005 · Cited by 590 · see citing works

Nonlinear pharmacokinetics and metabolism of paclitaxel and its pharmacokinetic/pharmacodynamic relationships in humans.

Gianni, L., Kearns, C. M., Giani, A., Capri, G., Viganò, L., Lacatelli, A., Bonadonna, G., & Egorin, M. J. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.1.180 · Cited by 553 · see citing works

Comparative Preclinical and Clinical Pharmacokinetics of a Cremophor-Free, Nanoparticle Albumin-Bound Paclitaxel (ABI-007) and Paclitaxel Formulated in Cremophor (Taxol)

Sparreboom, A., Scripture, C. D., Trieu, V. N., Williams, P. J., De, T., Yang, A. J., Beals, B., Figg, W. D., Hawkins, M., & Desai, N. P. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2291 · Cited by 506 · see citing works

Paclitaxel Versus Doxorubicin as First-Line Single-Agent Chemotherapy for Metastatic Breast Cancer: A European Organization for Research and Treatment of Cancer Randomized Study With Cross-Over

Paridaens, R., Biganzoli, L., Bruning, P. F., Klijn, J. G. M., Gamucci, T., Houston, S. J., Coleman, R. E., Schachter, J., Vreckem, A. V., Sylvester, R. J., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.4.724 · Cited by 364 · see citing works

Untitled work

(1999) · PubMed · Cited by 337 · see citing works

Role of Formulation Vehicles in Taxane Pharmacology

van Zuylen, L., Verweij, J., & Sparreboom, A. (2001) · Investigational New Drugs · doi:10.1023/a:1010618632738 · Cited by 294 · see citing works

Phase I and Pharmacokinetics Trial of ABI-007, a Novel Nanoparticle Formulation of Paclitaxel in Patients With Advanced Nonhematologic Malignancies

Nyman, D. W., Campbell, K. J., Hersh, E. M., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2004.00.6148 · Cited by 286 · see citing works

Failure of Higher-Dose Paclitaxel to Improve Outcome in Patients With Metastatic Breast Cancer: Cancer and Leukemia Group B Trial 9342

Winer, E. P., Berry, D. A., Woolf, S., Duggan, D. B., Kornblith, A. B., Harris, L. N., Michaelson, R. A., Kirshner, J., Fleming, G. F., Perry, M. C., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.048 · Cited by 270 · see citing works

Quantitative analysis of albumin uptake and transport in the rat microvessel endothelial monolayer

John, T. A., Vogel, S. M., Tiruppathì, C., Malik, A. B., & Minshall, R. D. (2003) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00152.2002 · Cited by 269 · see citing works

Multicenter Phase II Trial of ABI-007, an Albumin-Bound Paclitaxel, in Women With Metastatic Breast Cancer

Ibrahim, N. K., Samuels, B. L., Page, R. D., Doval, D. C., Patel, K. M., Rao, S., Nair, M. K., Bhar, P., Desai, N. P., & Hortobágyi, G. N. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.11.013 · Cited by 267 · see citing works

Preclinical Pharmacology of the Taxanes: Implications of the Differences

Gligorov, J., & Lotz, J. P. (2004) · The Oncologist · doi:10.1634/theoncologist.9-suppl_2-3 · Cited by 246 · see citing works

Paclitaxel and recombinant human granulocyte colony-stimulating factor as initial chemotherapy for metastatic breast cancer.

Reichman, B. S., Seidman, A. D., Crown, J. P., et al. (1993) · Journal of Clinical Oncology · doi:10.1200/jco.1993.11.10.1943 · Cited by 237 · see citing works

Distribution of SPARC in normal and neoplastic human tissue.

Porter, P. L., Sage, E. H., Lane, T. F., Funk, S. E., & Gown, A. M. (1995) · Journal of Histochemistry & Cytochemistry · doi:10.1177/43.8.7622842 · Cited by 209 · see citing works

Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.

Seidman, A. D., Tiersten, A., Hudis, C. A., et al. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.10.2575 · Cited by 204 · see citing works

Vesicle formation and trafficking in endothelial cells and regulation of endothelial barrier function

Minshall, R. D., Tiruppathì, C., Vogel, S. M., et al. (2002) · Histochemistry and Cell Biology · doi:10.1007/s00418-001-0367-x · Cited by 203 · see citing works

High affinity binding of paclitaxel to human serum albumin

Paál, K., Müller, J., & Hegedûs, L. (2001) · European Journal of Biochemistry · doi:10.1046/j.1432-1327.2001.02107.x · Cited by 191 · see citing works

Interaction of taxol with human serum albumin

Purcell, M., Neault, J. F., & Tajmir‐Riahi, H. A. (2000) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(99)00251-4 · Cited by 190 · see citing works

Albumin uptake and transcytosis in endothelial cells in vivo induced by albumin-binding protein

Vogel, S. M., Minshall, R. D., Pilipović, M., et al. (2001) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.2001.281.6.l1512 · Cited by 184 · see citing works

Description of a short-term Taxol®-induced nociceptive neuropathy in rats

Authier, N., Gillet, J.-P., Fialip, J., Eschalier, A., & Coudore, F. (2000) · Brain Research · doi:10.1016/s0006-8993(00)02910-3 · Cited by 171 · see citing works

Suspected anaphylactic reaction to Cremophor EL.

Dye, D., & Watkins, J. (1980) · BMJ · doi:10.1136/bmj.280.6228.1353 · Cited by 170 · see citing works

Sequence-dependent alteration of doxorubicin pharmacokinetics by paclitaxel in a phase I study of paclitaxel and doxorubicin in patients with metastatic breast cancer.

Holmes, F. A., Madden, T. L., Newman, R. A., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.10.2713 · Cited by 166 · see citing works

Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer.

Piccart, M. J., Klijn, J. G. M., Paridaens, R., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.9.3149 · Cited by 161 · see citing works

Randomized Trial of 3-Hour Versus 24-Hour Infusion of High-Dose Paclitaxel in Patients With Metastatic or Locally Advanced Breast Cancer: National Surgical Adjuvant Breast and Bowel Project Protocol B-26

Smith, R. E., Brown, A. M., Mamounas, E. P., Anderson, S., Lembersky, B. C., Atkins, J. H., Shibata, H. R., Báez, L., DeFusco, P. A., Davila, E., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.11.3403 · Cited by 152 · see citing works

Taxanes: an overview of the pharmacokinetics and pharmacodynamics

Vaishampayan, U. N., Parchment, R. E., Jasti, B., & Hussain, M. (1999) · Urology · doi:10.1016/s0090-4295(99)00451-3 · Cited by 145 · see citing works

Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens

Kloover, J. S., den Bakker, M. A., Gelderblom, H. A. J., & van Meerbeeck, J. P. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601303 · Cited by 138 · see citing works

Targeting the Microtubules in Breast Cancer Beyond Taxanes: The Epothilones

Cortés, J., & Baselga, J. M. (2007) · The Oncologist · doi:10.1634/theoncologist.12-3-271 · Cited by 137 · see citing works

Phase I/II Trial of Weekly Intravenous 130-nm Albumin-Bound Paclitaxel As Initial Chemotherapy in Patients With Stage IV Non–Small-Cell Lung Cancer

Rizvi, N. A., Riely, G. J., Azzoli, C. G., Miller, V. A., Ng, K., Fiore, J. J., Chia, G., Brower, M., Heelan, R. T., Hawkins, M., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.10.8605 · Cited by 121 · see citing works

Potential neurotoxicity of the solvent vehicle for cyclosporine.

Windebank, A. J., Blexrud, M. D., & de Groen, P. C. (1994) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)38962-7 · Cited by 107 · see citing works

Preclinical pharmacology of docetaxel

Bissery, M.-C. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)00357-o · Cited by 83 · see citing works

Phase I and pharmacokinetic trial of carboplatin and albumin-bound paclitaxel, ABI-007 (Abraxane®) on three treatment schedules in patients with solid tumors

Stinchcombe, T. E., Socinski, M. A., Walko, C. M., O’Neil, B. H., Collichio, F. A., Ivanova, A., Mu, H., Hawkins, M., Goldberg, R. M., Lindley, C. M., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0423-x · Cited by 79 · see citing works

A Novel Intraarterial Chemotherapy Using Paclitaxel in Albumin Nanoparticles to Treat Advanced Squamous Cell Carcinoma of the Tongue: Preliminary Findings

DAMASCELLI, B., Patelli, G., Lanocita, R., Tolla, G. D., Frigerio, L. F., Marchianò, A. V., Garbagnati, F., Spreafico, C., Tichà, V., Regna‐Gladin, C., et al. (2003) · American Journal of Roentgenology · doi:10.2214/ajr.181.1.1810253 · Cited by 77 · see citing works

Histamine release and hypotensive reactions in dogs by solubilizing agents and fatty acids: Analysis of various components in cremophor El and development of a compound with reduced toxicity

Lorenz, W., SCHMAL, A., SCHULT, H., Lang, S., Ohmann, C., Weber, D., Kapp, B., Lüben, L., & Doenicke, Α. (1982) · Inflammation Research · doi:10.1007/bf01965109 · Cited by 76 · see citing works

Anaphylaxis to Intravenous Cyclosporine and Tolerance to Oral Cyclosporine: Case Report and Review

Volcheck, G. W., & Dellen, R. G. V. (1998) · Annals of Allergy Asthma & Immunology · doi:10.1016/s1081-1206(10)62949-3 · Cited by 67 · see citing works

Personal Recollections on the Early Development of Taxol

Horwitz, S. B. (2003) · Journal of Natural Products · doi:10.1021/np0304464 · Cited by 67 · see citing works

Effect of the paclitaxel vehicle, Cremophor EL, on the pharmacokinetics of doxorubicin and doxorubicinol in mice

Webster, L., Cosson, E., Stokes, K. H., et al. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.90 · Cited by 65 · see citing works

Practical Aspects of Weekly Docetaxel Administration Schedules

Hainsworth, J. D. (2004) · The Oncologist · doi:10.1634/theoncologist.9-5-538 · Cited by 55 · see citing works

The pharmacokinetics of a 1-h paclitaxel infusion

Mross, K. B., Holl�nder, N., Hauns, B., et al. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051020 · Cited by 54 · see citing works

Phase I trial of cremophor EL with bolus doxorubicin.

Millward, M., Webster, L., Rischin, D., Stokes, K. H., Toner, G. C., Bishop, J. F., Olver, I., Linahan, B. Μ., Linsenmeyer, M. E., & Woodcock, D. M. (1998) · PubMed · Cited by 37 · see citing works

Pharmacokinetics of the Taxanes

Kearns, C. M. (1997) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/j.1875-9114.1997.tb03812.x · Cited by 35 · see citing works

Assessment of neurotoxicity following repeated cremophor / ethanol injections in rats

Authier, N., Gillet, J.-P., Fialip, J., et al. (2001) · Neurotoxicity Research · doi:10.1007/bf03033269 · Cited by 33 · see citing works

Taxanes in combined-modality therapy for solid tumors.

Choy, H. (1999) · PubMed · Cited by 33 · see citing works

Randomized comparison of weekly or every-3-week (q3w) nab-paclitaxel compared to q3w docetaxel as first-line therapy in patients (pts) with metastatic breast cancer (MBC)

Gradishar, W., Krasnojon, D., Cheporov, S. V., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.1032 · Cited by 29 · see citing works

Pharmacokinetic profiles of doxorubicin in combination with taxanes

Holmes, F. A., & Rowinsky, E. K. (2001) · Seminars in Oncology · doi:10.1053/sonc.2001.26435 · Cited by 28 · see citing works

North Central Cancer Treatment Group N0531: Phase II Trial of Weekly Albumin-Bound Paclitaxel (ABI-007; Abraxane®) in Combination with Gemcitabine in Patients with Metastatic Breast Cancer

Moreno‐Aspitia, A., & Perez, E. A. (2005) · Clinical Breast Cancer · doi:10.3816/cbc.2005.n.042 · Cited by 23 · see citing works

Pharmacokinetic profiles of doxorubicin in combination with taxanes

Holmes, F. A., & Rowinsky, E. K. (2001) · Seminars in Oncology · doi:10.1016/s0093-7754(01)90194-0 · Cited by 23 · see citing works

Randomized study comparing nab-paclitaxel with solvent-based paclitaxel in Chinese patients (pts) with metastatic breast cancer (MBC)

Guan, Z., Feng, F., Li, Q. L., Jiang, Z., Shen, Z., Yu, S., Feng, J., Huang, J., Yao, Z., & Hawkins, M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.1038 · Cited by 21 · see citing works

Phase II trial of nab-paclitaxel (nanoparticle albumin-bound paclitaxel (ABX)) + capecitabine (XEL) in first-line treatment of metastatic breast cancer (MBC)

Somer, B. G., Schwartzberg, L. S., Arena, F. P., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.1053 · Cited by 17 · see citing works

An open-label, phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab in first-line patients with advanced non-squamous non-small cell lung cancer (NSCLC)

Reynolds, C., Barrera, D., Vu, D. Q., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.7610 · Cited by 15 · see citing works

347 Steroids do reduce the severity and delay the onset of docetaxel (DXT) induced fluid retention: Final results of a randomized trial of the EORTC investigational drug branch for breast cancer (IDBBC)

Piccart, M. J., Klijn, J. G. M., Paridaens, R., et al. (1995) · European Journal of Cancer · doi:10.1016/0959-8049(95)95600-b · Cited by 13 · see citing works

Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC)

Hawkins, M., Manikhas, G., Makhson, A. N., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.7659 · Cited by 5 · see citing works

Results of a phase II evaluation of nanoparticle albumin bound paclitaxel (nab-paclitaxel) in platinum-sensitive patients with recurrent ovarian, peritoneal, or fallopian tube cancer

Teneriello, M. G., Tseng, P. C., Crozier, M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.5525 · Cited by 5 · see citing works

NCCTG phase II trial N0531of weekly nab-paclitaxel (nab-p) in combination with gemcitabine (gem) in patients with metastatic breast cancer (MBC)

Roy, V., LaPlant, B. R., Gross, G. G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.1048 · Cited by 4 · see citing works

Principles of nanoparticle design for overcoming biological barriers to drug delivery

Blanco, E., Shen, H., & Ferrari, M. (2015) · Nature Biotechnology · doi:10.1038/nbt.3330 · Cited by 7,002 · see citing works

Controlled drug delivery vehicles for cancer treatment and their performance

Senapati, S., Mahanta, A. K., Kumar, S., & Maiti, P. (2018) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-017-0004-3 · Cited by 2,167 · see citing works

Nanoparticle interaction with plasma proteins as it relates to particle biodistribution, biocompatibility and therapeutic efficacy

Aggarwal, P., Hall, J. B., McLeland, C. B., Dobrovolskaia, M. A., & McNeil, S. E. (2009) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2009.03.009 · Cited by 1,791 · see citing works

Challenges in Development of Nanoparticle-Based Therapeutics

Desai, N. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9339-4 · Cited by 1,173 · see citing works

Smart nanoparticles for cancer therapy

Sun, L., Liu, H., Ye, Y., Lei, Y., Islam, R., Tan, S., Tong, R., Miao, Y.-B., & Cai, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01642-x · Cited by 1,073 · see citing works

Minireview: Nanoparticles and the Immune System

Zolnik, B. S., González-Fernández, A., Sadrieh, N., & Dobrovolskaia, M. A. (2010) · Endocrinology · doi:10.1210/en.2009-1082 · Cited by 914 · see citing works

Mechanisms of drug release in nanotherapeutic delivery systems

Wong, P. T., & Choi, S. K. (2015) · Chemical Reviews · doi:10.1021/cr5004634 · Cited by 507 · see citing works

Recent progress in biomedical applications of pluronic (PF127): Pharmaceutical perspectives

Akash, M. S. H., & Rehman, K. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.04.032 · Cited by 394 · see citing works

Positioning metal-organic framework nanoparticles within the context of drug delivery – A comparison with mesoporous silica nanoparticles and dendrimers

Wuttke, S., Lismont, M., Escudero, A., Rungtaweevoranit, B., & Parak, W. J. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.01.025 · Cited by 286 · see citing works

A high capacity polymeric micelle of paclitaxel: implication of high dose drug therapy to safety and in vivo anti-cancer activity

He, Z., Wan, X., Schulz, A., Bludau, H., Dobrovolskaia, M. A., Stern, S. T., Montgomery, S. A., Yuan, H., Li, Z., Alakhova, D., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.06.002 · Cited by 197 · see citing works

Nucleolin Targeting AS1411 Modified Protein Nanoparticle for Antitumor Drugs Delivery

Wu, J., Song, C., Jiang, C., Shen, X., Qiao, Q., & Hu, Y. (2013) · Molecular Pharmaceutics · doi:10.1021/mp300686g · Cited by 125 · see citing works

Novel Therapeutic Strategies for Alzheimer’s Disease: Implications from Cell-Based Therapy and Nanotherapy

Derakhshankhah, H., Sajadimajd, S., Jafari, S., Izadi, Z., Sarvari, S., Sharifi, M., Falahati, M., Moakedi, F., Muganda, W. C. A., Müller, M., et al. (2020) · Nanomedicine: Nanotechnology, Biology and Medicine · doi:10.1016/j.nano.2020.102149 · Cited by 48 · see citing works

Protein-Protein Interactions as Drug Targets

Wendt, M. D. (2012) · Topics in Medicinal Chemistry · doi:10.1007/978-3-642-28965-1_1 · Cited by 9 · see citing works

Delivering more for less: nanosized, minimal-carrier and pharmacoactive drug delivery systems

Etter, E. L., Mei, K., & Nguyen, J. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113994 · Cited by 102 · see citing works

Lipid Based Vesicular Drug Delivery Systems

Jain, S., Jain, V., & Mahajan, S. C. (2014) · Advances in Pharmaceutics · doi:10.1155/2014/574673 · Cited by 183 · see citing works

Recent advances in drug delivery systems

(1985) · General Pharmacology The Vascular System · doi:10.1016/0306-3623(85)90031-x · Cited by 83 · see citing works

RESEALED ERYTHROCYTE: A NOVEL DRUG DELIVERY SYSTEM

Gatkal, S. H., Gaikwad, N. M., & Patil, P. M. (2012) · Cited by 1 · see citing works

Two Important Polysaccharides as Carriers for Drug Delivery

Huang, G., Chen, Y., Li, Y., et al. (2015) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/1389557515666150709115945 · Cited by 8 · see citing works